Synergistic associations of metformin and GLP‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes
Abstract Background Metformin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of adiposity-related cancers in patients with type 2 diabetes (T2D). The potential synergistic effects of these treatments on cancer incidence remain unclear, considering their distinct biological mechanisms and their associated effects on body weight. Methods A retrospective cohort analysis was conducted […]
The ‘After Phase’ Is Missing: Why Every GLP-1 Prescription Needs an Exit
By HOLLI BRADISH-LANE I’ve seen clients start GLP-1 medications full of hope—and stop them feeling betrayed by their own biology. Some reached their limit with side effects: relentless nausea, fatigue, or the quiet loss of joy in eating. Others simply couldn’t afford to stay on. A few never saw the promised results at all. But […]
Cantor Fitzgerald Reaffirms Price Target on Eli Lilly (LLY) Despite GLP-1 Setback
Post Content
GI Risks Similar Among GLP-1 Drugs, but Higher Than With SGLT-2 Inhibitors
(MedPage Today) — Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type 2 diabetes, although all higher than seen with sodium-glucose cotransporter 2 (SGLT-2) inhibitors, according…
Your Medication Might Be Giving You Nightmares
If you’ve been having frequent disturbing dreams and there isn’t an obvious link to what’s happening in your waking life, it may be time to check your medicine cabinet. Many people aren’t aware that common medications can have a negative influence on their dreams. Certain antidepressants, beta blockers to treat high blood pressure, statins to […]
Study shows semaglutide, tirzepatide and dulaglutide have similar gastrointestinal safety profiles in clinical settings
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that the medications have similar gastrointestinal safety profiles among those with T2D, providing clinicians with evidence to weigh the risks and benefits of these medications for their patients.
Lilly earmarks $3B for new European obesity pill factory
Eli Lilly plans to build another facility to make its oral GLP-1 drug orforglipron. The $3 billion site will be located in Katwijk, the Netherlands. In addition to orforglipron, the new site will make other …
Did Novo Nordisk Just Say “Checkmate” to Pfizer?
Novo Nordisk‘s (NYSE: NVO) shares have dropped significantly over the past year, partly due to clinical setbacks in its core GLP-1 portfolio. However, the Denmark-based pharmaceutical leader has been trying to turn things around. The company has expanded its pipeline through internal innovation and astute acquisitions. The latest buyout Novo Nordisk is trying to pull […]
Pfizer Lawsuits Allege Novo Nordisk’s Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal
Pfizer claims Metsera breached their merger agreement, adding that a tie-up of the biotech with GLP-1 drug giant Novo Nordisk would violate U.S. antitrust law. Metsera called the arguments “nonsense” and said Pfizer is trying to buy the obesity drug developer for less than what Novo is willing to pay. The post Pfizer Lawsuits Allege […]
GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research
Cancer diagnoses are prevalent in people with obesity and type 2 diabetes, and abundant clinical evidence supports the protective effects of weight loss for cancer prevention. Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized obesity and type 2 diabetes medicine and alleviate many comorbidities of these metabolic diseases. In this Review, we summarize the current clinical […]